-
BIOPSEE Series A+ Financing Confocal Microendoscope
•
BIOPSEE, a Hubei-based microendoscope specialist, has raised tens of millions of renminbi in a Series A+ financing round led by Ezhou Changda Investment, Suzhou High-Tech Venture Capital, Suzhou Kejicheng Venture Capital, and SND Group. The funds will support research and development, scaled manufacturing, and clinical applications of confocal microendoscope products.…
-
CSPC Pharmaceutical’s DBPR108 Hits Endpoints in Type 2 Diabetes Trials
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its Category 1 drug DBPR108 has achieved endpoints in two Phase III clinical studies for type 2 diabetes. The oral dipeptidyl peptidase-IV (DPP-4) inhibitor demonstrated efficacy both as a monotherapy and in combination with other drugs, recruiting over 1,000 patients in…
-
Shanghai Pharmaceuticals Gets NMPA Approval for B013 in Triple-Negative Breast Cancer
•
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products Administration (NMPA) to conduct a Phase II/III clinical trial of its Category 1 biologic B013, combined with albumin paclitaxel, for first-line treatment of locally advanced or metastatic triple-negative breast cancer (TNBC). Drug ProfileB013, a potential first-in-class…
-
Scitop Bio-tech’s KEX02 Live Bacteria Therapy Gets FDA IND Approval for NSCLC
•
Beijing Scitop Bio-tech Co., Ltd (SHE: 300858) announced that the US Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its live bacteria therapeutic candidate KEX02, to be tested in combination with a PD-1 inhibitor for the treatment of non-small cell lung cancer (NSCLC). About KEX02KEX02…
-
Sanyou Biopharmaceuticals and KangaBio Ink Licensing Deal for Antibody Drug Candidate
•
Shanghai-based Sanyou Biopharmaceuticals Co., Ltd and KangaBio have entered into a licensing agreement, granting Kanga exclusive rights to research, develop, manufacture, and commercialize Sanyou’s in-house antibody drug candidate. Financial details of the deal were not disclosed. Agreement DetailsThe agreement builds on a previous licensing term list for two of Sanyou’s…
-
InnoCare Pharma’s 2022 Interim Report Shows Strong Revenue Growth Driven by Orelabrutinib Sales
•
China-based InnoCare Pharma (HKG: 9969) announced its 2022 interim financial results, reporting total revenues of RMB 246 million (USD 36 million), a 142% year-on-year (YOY) increase. The growth was primarily driven by a 115% sales volume increase of its Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib, which was added to the…
-
Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform
•
Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion of a Series B financing round totaling RMB 520 million (USD 76.1 million). The round was led by China Merchants Health Industry Holding Co., Ltd, with participation from CMS Capital, China Merchants Security, Fosun Health…
-
Nuance Pharma Gets NMPA Green Light for Ensifentrine COPD Trials in China
•
China-based Nuance Pharma has secured approval from the National Medical Products Administration (NMPA) to conduct both Phase I and Phase III clinical trials for ensifentrine, a dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), as a maintenance treatment for chronic obstructive pulmonary disease (COPD). Partnership and DevelopmentThe drug…
-
Lundbeck’s Vyepti Fails to Accelerate China Launch via SUNLIGHT Trial
•
Lundbeck’s attempt to fast-track migraine drug Vyepti (eptinezumab) into China and Asia via the SUNLIGHT trial has failed to meet primary endpoints, according to the firm’s Q2 2022 financial report and subsequent earnings call. The drug, approved in the US in February 2020 and in Europe in January 2022, saw…
-
Mindray Bio-Medical’s H1 2022 Revenues Jump 20.17% to RMB 15.3B
•
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) reported robust financial results for H1 2022, with revenues reaching RMB 15.3 billion (USD 2.24 billion), up 20.17% year-on-year (YOY). Net profits rose 21.71% YOY to RMB 5.28 billion (USD 773 million). Business Segments R&D InvestmentMindray invested RMB 1.45 billion (USD 212…
-
JJET Raises RMB 700M in Series A+ and B Rounds for Cardiac Electrophysiology Products
•
JJET, a Chengdu-based specialist in cardiac electrophysiology interventional therapy, has completed Series A+ and Series B financing rounds, raising a total of RMB 700 million (USD 102.5 million). Investors include SinoRock, Guanghua Wutong Equity Investment Fund, YuanHengLiZhen, Weigao Holding, and HM Capital. The funding follows a Series A round led…
-
IASO Biotherapeutics’ BCMA CAR-T Therapy Approved for NMOSD in China
•
China-based IASO Biotherapeutics announced that the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for equecabtagene autoleucel (CT103A), a BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, for the treatment of neuromyelitis optica spectrum disorder (NMOSD). This marks the first global trial of a BCMA…
-
Hengrui Medicine’s H1 2022 Revenues Drop 23% Amid Generic Price Cuts and COVID-19 Disruptions
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) reported a 23.08% year-on-year (YOY) decline in revenues to RMB 10.22 billion (USD 1.49 billion) for H1 2022, with net profits falling 24.12% YOY to RMB 2 billion (USD 292.8 million). The company attributed the downturn to volume-based procurement (VBP) price cuts, inclusion…
-
Allist Pharmaceuticals Receives NMPA Approval for Furmonertinib in Exon 20 Insertion NSCLC
•
Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) announced that the National Medical Products Administration (NMPA) has approved a clinical trial for its furmonertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, targeting exon 20 insertion mutated non-small cell lung cancer (NSCLC). Drug ProfileFurmonertinib received conditional market approval from the NMPA in…
-
Daiichi Sankyo’s Enhertu Accepted for Review in China for HER2-Low Breast Cancer
•
Japan-based Daiichi Sankyo Inc. (TYO: 4568) announced that its market approval filing for Enhertu (T-DXd, trastuzumab deruxtecan), a HER2 antibody drug conjugate (ADC), has been accepted for review by the Center for Drug Evaluation (CDE) in China. The filing seeks approval for the treatment of adult patients with unresectable or…
-
NHSA Proposes Regulations to Standardize Oral Implant Charges and Reduce Costs
•
The National Healthcare Security Administration (NHSA) has released a draft proposal titled “Notice on Carrying out Special Treatment of Oral Implant Medical Service Charges and Consumables Prices,” seeking public feedback until August 27, 2022. The initiative aims to address issues such as irregular charges and heavy cost burdens in the…
-
Ping An Good Doctor Reports 2022 Interim Results with Revenue Decline and User Growth
•
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor, has released its 2022 interim financial report. The report reveals a year-on-year (YOY) decline in total revenue and gross profits, alongside a significant reduction in net losses and continued growth in the number of…
-
WuXi STA Breaks Ground on New US Manufacturing Site in Delaware
•
WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced the commencement of construction on a new manufacturing site in Delaware, United States. The 190-acre campus in Middletown, first announced in June 2021, will serve as STA’s second facility in the US. Key Details of the New…
-
ZhenGe Biotech Secures RMB 100 Million in Series C+ Funding for CDMO Expansion
•
China-based Contract Development and Manufacturing Organization (CDMO) ZhenGe Biotech has reportedly raised RMB 100 million (USD 14.6 million) in a Series C+ financing round. The funding was backed by Guoyao Zhongjin (Shanghai) Medical Health Investment, ZhangKeHeRun Fund, Lingang Lanwan Private Equity Fund, and SPINNOTEC/Haiwang Capital. With this latest round, ZhenGe…
